---
title: "Oruka Therapeutics, Inc. (ORKA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ORKA.US.md"
symbol: "ORKA.US"
name: "Oruka Therapeutics, Inc."
industry: "生物技術"
---

# Oruka Therapeutics, Inc. (ORKA.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [orukatx.com](https://orukatx.com) |

## Company Profile

Oruka Therapeutics, Inc.是一家臨床階段的生物制藥公司，專注于開發用于銀屑病（PsO）及其他炎症和免疫（I&I）適應症的新型單克隆抗體治療藥物。其主要產品包括針對白介素-23 的 p19 亞單位的 ORKA-001，目前正在進行銀屑病治療的第一階段臨床試驗；以及針對白介素-17A 和白介素-17F 的 ORKA-002，用于治療銀屑病、銀屑病關節炎及其他疾病。該公司還開發了針對未公開通路的 ORKA-003；以及 ORKA-021，這是 ORKA-002 和 ORKA-001 的序貫組合方案。Oruka Therapeutics, Inc

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -19.93 | 508/606 | - | - | - |
| PB | 3.44 | 248/606 | 3.22 | 1.67 | 1.13 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 11 | 85% |
| Overweight | 2 | 15% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.28 |
| Highest Target | 49.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ORKA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ORKA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ORKA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.